From injury to repair: the therapeutic potential of induced pluripotent stem cells in heart failure

Heart failure is a complex clinical syndrome characterized by the heart’s inability to pump sufficient blood to meet the body’s metabolic demands, resulting in symptoms such as dyspnea, fatigue, and fluid retention. Despite significant advances in pharmacological treatments and device therapies, the prognosis for patients with advanced heart failure remains poor. This underscores the urgent need for innovative regenerative therapies aimed at restoring cardiac function and improving the quality of life for patients suffering from this debilitating condition. This article provides a comprehensive overview of the pathophysiologic mechanisms underlying end-stage heart failure, which include myocardial systolic and diastolic dysfunction, neuroendocrine activation, inflammation, and oxidative stress. Collectively, these mechanisms lead to the progressive deterioration of cardiac structure and function, culminating in heart failure. The article also examines the differences between ischemic and non-ischemic cardiomyopathies and their implications for treatment strategies and prognosis. Furthermore, the review explores the application of regenerative medicine in end-stage heart failure, focusing on its potential for cardiac repair and functional recovery. In the field of regenerative medicine, induced pluripotent stem cells and their derived cardiomyocytes are considered cutting-edge technologies for cardiac repair. Induced pluripotent stem cells can differentiate into functional cardiomyocytes, thereby offering new hope for cardiac regeneration. However, current research faces several challenges, including the maturity and functional integration of induced pluripotent stem cells derived cardiomyocytes, immunogenicity concerns, and difficulties in scaling up production for clinical applications. Additionally, ethical issues related to induced pluripotent stem cell technology, such as cell sourcing and potential tumorigenic risks, must be carefully addressed. The article highlights the significant potential of induced pluripotent stem cell technology in treating end-stage heart failure while emphasizing the complexities involved in transitioning from laboratory research to clinical practice.